Trials / Completed
CompletedNCT03750175
OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -
OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer - Feasibility Study Investigating Circulating Tumor DNA for Treatment Decisions
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 49 (actual)
- Sponsor
- Karen-Lise Garm Spindler · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The present study will investigate the feasibility and clinical value of using circulating tumor DNA as selection for anti-epidermal growth factor receptor treatment for metastatic colorectal cancer.
Detailed description
The primary aim of this prospective study is to investigate if cfDNA in plasma is feasible and reliable for selection of mCRC patients who will benefit of anti-EGFR monoclonal antibody therapy Secondary, to analyze developments in mutational status as reflected by cfDNA in plasma during therapy and at time of progression
Conditions
- Colorectal Cancer Metastatic
- Circulating Tumor DNA
- KRAS Gene Mutation
- NRAS Gene Mutation
- BRAF Gene Mutation
- Epidermal Growth Factor Receptor Inhibitor
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Plasma circulating DNA analysis | Clinical utility of ctDNA analysis for treatment decision |
Timeline
- Start date
- 2018-06-01
- Primary completion
- 2022-06-01
- Completion
- 2022-12-31
- First posted
- 2018-11-21
- Last updated
- 2023-02-03
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT03750175. Inclusion in this directory is not an endorsement.